Provided by Tiger Fintech (Singapore) Pte. Ltd.

AKESO

171.200
+8.2005.03%
Volume:11.49M
Turnover:1.93B
Market Cap:153.74B
PE:-259.16
High:173.200
Open:165.000
Low:161.400
Close:163.000
Loading ...

Akeso Inc. Receives Approval from NMPA and FDA to Initiate Global Registrational Trial of Cadonilimab for PD-1 Treatment-Resistant Hepatocellular Carcinoma

Reuters
·
04 Aug

Akeso Announces Approval to Initiate Global Registrational Trial of Cadonilimab (Pd-1/Ctla-4) for Pd-1 Treatment-Resistant Hepatocellular Carcinoma

THOMSON REUTERS
·
04 Aug

UBS Reiterates "Buy" Rating on AKESO (09926), Raises Target Price to HK$197.5

Stock News
·
01 Aug

Akeso Inc. Announces Launch of Phase III Clinical Trial for Ivonescimab in Treatment of IO-Resistant NSCLC

Reuters
·
31 Jul

Akeso Announces Completion of First Dosing in Phase Iii Clinical Trial of Ivonescimab (Pd-1/Vegf) Combination Therapy for Immunotherapy-Resistant Nsclc

THOMSON REUTERS
·
31 Jul

Akeso Inc. Announces NMPA Acceptance of sNDA for Ivonescimab Combined with Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer

Reuters
·
28 Jul

HK Movers | Biotechnology Stocks Jump With MicroPort up 20%

Tiger Newspress
·
24 Jul

HK Movers | Biotech Stocks Rally, Ascent Led by TYK Medicines and Sirnaomics

Tiger Newspress
·
24 Jul

Akeso Inc. Launches Phase III Trial of Ivonescimab for Metastatic Pancreatic Cancer Treatment

Reuters
·
24 Jul

Akeso Announces First Patient Enrollment in Phase Iii Trial of Ivonescimab for Pancreatic Cancer

THOMSON REUTERS
·
24 Jul

HK Movers | HK's Biotech Shares Soar. Fudan-zhangjiang Soars 22%; Akeso up 11%; CStone Pharma up 9%

Tiger Newspress
·
17 Jul

BOCOM International: Innovative Drug Sector's Recovery Prospects Remain Attractive; Focus on Commercial Insurance Drug Catalog Launch

Stock News
·
16 Jul

HK Movers | HK's Biotech Shares Soar. Livzon Pharma up 14%; Shandong Xinhua up 11%; Fosun Pharma up 8%

Tiger Newspress
·
16 Jul

Asian Stocks Estimated To Be Trading At Discounts Of Up To 26.6%

Simply Wall St.
·
16 Jul

FDA Lifts Veil on Drug Approval Process: Four Chinese Pharma Rejections Expose Overseas Expansion Challenges

Market Watcher
·
16 Jul

Akeso Inc. Announces Enrollment of First Patient in Phase III Trial of Ivonescimab for Advanced Metastatic Colorectal Cancer Treatment

Reuters
·
16 Jul

BOCOM International Raises Target Price for Akeso (09926) to HK$140, Maintains "Buy" Rating

Stock Track
·
15 Jul

BOCOM International Lifts AKESO Price Target to HK$140, Retains "Buy" Rating

Market Watcher
·
15 Jul

Bocom International Lifts AKESO (09926) Target Price to HK$140, Maintains Buy Rating

Stock Track
·
15 Jul

Akeso Inc. Submits List of Directors to HKEX

Reuters
·
04 Jul